Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Deciphera’s efforts to move it earlier in the treatment pathway have suffered some setbacks ... Daiichi Sankyo’s oral CSF-1, KIT, and FLT3 inhibitor Turalio (pexidartinib), has a black ...

This process mainly involves T cells, natural killer cells (NK cells), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), as well as ...